Table 1. Univariate and multivariate analysis of predictors associated with GG upgrading after RP in biopsy GG ≤2 cohort.
| Predictors | Univariate analysis | Multiple analysis | |||
|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||
| Age (years) | 1.050 (0.981, 1.124) | 0.16 | – | – | |
| BMI (kg/m2) | 0.988 (0.879, 1.111) | 0.84 | – | – | |
| tPSA ≥10 (ng/mL) | 3.431 (1.633, 7.210) | <0.001 | 2.645 (1.084, 6.456) | 0.03 | |
| fPSA >2.10 (ng/mL) | 1.599 (0.641, 3.988) | 0.31 | – | – | |
| AAPR >0.54 | 1.449 (0.726, 2.893) | 0.29 | – | – | |
| LDH >165.20 (U/L) | 1.079 (0.541, 2.153) | 0.83 | – | – | |
| SII >379.50 | 4.276 (2.036, 8.98) | <0.001 | 4.602 (1.940, 10.915) | 0.001 | |
| NLR >2.13 | 4.481 (2.137, 9.396) | <0.001 | – | – | |
| Clinical stage (cT3 + cT4) | 4.104 (1.42, 11.859) | 0.009 | – | – | |
| Number of positive cores >3 | 0.374 (0.173, 0.806) | 0.01 | 0.313 (0.131, 0.746) | 0.009 | |
| The percentage of positive cores >25% | 0.431 (0.201, 0.923) | 0.03 | – | – | |
| Preoperative neoadjuvant therapy (yes) | 0.905 (0.249, 3.288) | 0.88 | – | – | |
Preoperative neoadjuvant therapy: LHRH agonists including Goserelin or leuprorelin. GG, Gleason grade group; RP, radical prostatectomy; BMI, body mass index; tPSA, total prostate-specific antigen; fPSA, free prostate-specific antigen; AAPR, albumin-to-alkaline phosphatase ratio; LDH, lactate dehydrogenase; SII, systemic immune-inflammation index; NLR, neutrophil-lymphocyte ratio; OR, odds ratio; CI, confidence interval; LHRH, luteinizing hormone-releasing hormone.